Introduction {#s1}
============

Renal dysfunction is a worldwide health problem as a consequence of its adverse outcomes including cardiovascular events and all-cause-mortality [@pone.0088569-Go1]--[@pone.0088569-Perticone1]. Increasing evidence suggests that chronic kidney disease (CKD), defined as a sustained reduction in the glomerular filtration rate (GFR), and cardiovascular disease share common risk factors such as the metabolic syndrome and its individual components (elevated blood pressure, high plasma glucose levels, high triglycerides levels, low high density lipoprotein (HDL) levels, and abdominal obesity) [@pone.0088569-Fox1]--[@pone.0088569-Sesti1].

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countries [@pone.0088569-Browning1], comprising a large spectrum of disorders ranging from simple steatosis, to non-alcoholic steatohepatitis (NASH) with increasing levels of fibrosis, and, ultimately, cirrhosis [@pone.0088569-Angulo1], [@pone.0088569-Petta1]. While simple liver steatosis is considered as a non-progressive condition, NASH is a potentially harmful disorder associated with increased risk of liver-related morbidity and mortality [@pone.0088569-Bugianesi1]--[@pone.0088569-Rafiq1]. Like CKD, NAFLD has been linked to the same cluster of cardio-metabolic risk factors including the metabolic syndrome and its individual components [@pone.0088569-Marchesini1], [@pone.0088569-Stefan1], and is associated with increased risk of incident cardiovascular events [@pone.0088569-Adams1]--[@pone.0088569-Rafiq1], [@pone.0088569-Stepanova1], [@pone.0088569-Targher1]. Increasing evidence suggests that NAFLD/NASH and CKD share several traditional and non-traditional cardio-metabolic risk factors including higher plasma inflammatory and hemostatic factors, hyperuricemia, lower circulating insulin-like growth factor-1 (IGF-1) levels, endothelial dysfunction, and oxidative stress biomarkers [@pone.0088569-Targher1]--[@pone.0088569-Targher3]. Additionally, a number of studies has shown that liver biopsy--proven or ultrasonography-diagnosed NAFLD in adult subjects is associated with an increased prevalence [@pone.0088569-Targher3]--[@pone.0088569-Yasui1] and incidence [@pone.0088569-Chang1], [@pone.0088569-Targher6] of CKD. Interestingly, studies that used liver biopsy to diagnose NAFLD have shown that the severity of NASH histology (i.e., fibrosis stage) is associated with a more pronounced kidney dysfunction, independently of potential confounding factors, including the metabolic syndrome and its individual components [@pone.0088569-Targher5], [@pone.0088569-Yasui1]. Liver biopsy is considered the gold standard for the assessment of hepatic fibrosis and inflammation severity in subjects with chronic liver disease but has a number of limitations, including sampling variability, invasiveness, complications, and costs [@pone.0088569-Myers1] making it unfeasible for large epidemiological studies. In an attempt to overcome these problems, several noninvasive scoring indexes have been developed by combining clinical and biochemical parameters that are useful to categorize subjects with NAFLD in subgroups at low and high risk of advanced fibrosis [@pone.0088569-Wai1]--[@pone.0088569-Demir1]. Recent studies have shown that advanced fibrosis, as determined by the noninvasive NAFLD fibrosis score [@pone.0088569-Angulo2], is a significant predictor of mortality, mainly from cardiovascular causes, in individuals with ultrasonography-diagnosed NAFLD [@pone.0088569-Treeprasertsuk1], [@pone.0088569-Kim1]. The clinical utility of NAFLD fibrosis score in assessing CKD in individuals with ultrasonography-diagnosed NAFLD is still unsettled. In the present study, we therefore determined whether the severity of liver fibrosis estimated by the NAFLD fibrosis score is associated with higher prevalence of CKD among individuals with ultrasonography-diagnosed NAFLD.

Materials and Methods {#s2}
=====================

The study group comprised 570 White individuals participating to the CATAnzaro MEtabolic RIsk factors (CATAMERI) study, a cross-sectional study assessing cardio-metabolic risk factors in individuals carrying at least one risk factor including dysglycemia, overweight/obesity, hypertension, dyslipidemia, and family history for diabetes [@pone.0088569-Succurro1]. Information regarding medical history, drug use, alcohol, and cigarette consumption were collected. Exclusion criteria included: history of malignant disease, liver cirrhosis, gout, chronic gastrointestinal diseases, chronic pancreatitis, regular use of steatosis-inducing drugs, self-reporting alcohol intake of 3 or more drinks per day, positivity for antibodies to hepatitis C virus (HCV) or hepatitis B surface antigen (HBsAg). Clinical cardiovascular disease was excluded on the basis of medical history and resting electrocardiogram.

All anthropometric and serological measurements were made in the morning after a 12-h fasting using standardized methods. Brachial blood pressure was measured in the left arm of the supine subjects, after 5 min of quiet rest, with a digital electronic tensiometer (regular or large adult cuffs were used according to arm circumference). A minimum of three blood pressure readings were taken on three separate occasions at least 2 weeks apart, and the medians of these three values were used. A 75 g oral glucose tolerance test (OGTT) was performed with sampling for plasma glucose.

Liver ultrasonography was performed in all participants by the same trained operator, who was blinded to participants\' details, using a Toshiba Aplio 50 ultrasound apparatus equipped with a 3.5-MHz linear transducer [@pone.0088569-Arturi1], [@pone.0088569-Hribal1]. Longitudinal, sub costal, ascending, and oblique scans were performed. The ultrasonographic criteria used to diagnose fatty liver included liver and kidney echo discrepancy, the presence of an increased liver echogenicity or "bright liver", poor echo penetration into the deep portion of the liver, and vascular blurring either singly or in combination.

The protocol was approved by the local ethical committee (Comitato Etico Azienda Ospedaliera "Mater Domini", Catanzaro, Italy), and written informed consent was obtained from all participants in accordance with principles of Helsinki Declaration.

Analytical determinations {#s2a}
-------------------------

Glucose, triglycerides, total and HDL cholesterol concentrations were determined by enzymatic methods (Roche, Basel, Switzerland). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were measured using the α-ketoglutarate reaction; gamma-glutamyltransferase (GGT) levels with the L-gamma-glutamyl-3-carboxy-4-nitroanilide rate method. Serum creatinine was measured in the routine laboratory by an automated technique based on a Creatinine Jaffè compensated method for serum and plasma (Roche Diagnostics) implemented in an auto-analyzer. Serum uric acid was measured by the URICASE/POD method implemented in an auto-analyzer (Boehringer Mannheim, Mannheim, Germany). Albumin concentration was determined with a Alb2 kit on a Cobas C6000 analyzer (Roche Diagnostics, Milan, Italy). High sensitivity C-reactive protein (hsCRP) levels were measured by automated instrument (CardioPhase® hsCRP, Milan, Italy). An automated nephelometric technology using the BN™ II System analyzer (Siemens Healthcare, Italy) was employed to measure plasma fibrinogen concentrations. Plasma insulin concentration was measured with a chemiluminescence-based assay (Immulite®, Siemens, Italy), and total serum IGF-1 concentrations were determined by chemiluminescent immunoassay (Nichols Institute Diagnostic, San Juan Capistrano, CA).

Definitions {#s2b}
-----------

Glucose tolerance status was diagnosed according to the American Diabetes Association (ADA) criteria [@pone.0088569-The1]: normal glucose tolerance (NGT) when fasting plasma glucose (FPG) was \<5.6 mmol/l and 2 h post-load \<7.8 mmol/l, isolated impaired fasting glucose (IFG) when FPG was 5.6--6.9 mmol/l and 2 h post-load \<7.8 mmol/l, impaired glucose tolerance (IGT) when FPG was ≤6.9 mmol/l and 2-h post-load was 7.8--11.0 mmol/l, type 2 diabetes when FPG was ≥7.0 mmol/l and/or 2 h post-load was ≥11.1 mmol/l.

The NAFLD fibrosis score was calculated according to the following formula: −1.675 + 0.0373 x age + 0.0943 x BMI +1.13 x IFG or diabetes (yes = 1, no = 0) + 0.99 x AST/ALT ratio −0.013 x platelet − 0.66 x albumin [@pone.0088569-Arturi1]. Two cutoff points (\>0.676 and \<−1.455) were used to divide the subjects in three groups: low risk of fibrosis (\< −1.455), intermediate risk of fibrosis (−1.455--0.676), and high risk of fibrosis (\>0.676) [@pone.0088569-Angulo2].

The homeostasis model assessment index of insulin resistance (HOMA-IR) was calculated as fasting insulin × fasting glucose/22.5 [@pone.0088569-Matthews1].

Estimated glomerular filtration rate (eGFR) was calculated by using the CKD-EPI equation [@pone.0088569-Levey1]: eGFR =  141 x min(Scr/k, 1)^α^ x max(Scr/k, 1)^−1.209^ x 0.993^Age^ x 1.018 \[if female\], where Scr is serum creatinine, k is 0.7 for females and 0.9 for males, α is −0.329 for females and −0.411 for males, min indicates the minimum of Scr/k or 1, and max indicates the maximum of Scr/k or 1. CKD was defined as eGFR \<60 ml/min/1.73 m^2^.

Metabolic syndrome was defined as having three or more of the following criteria [@pone.0088569-Alberti1]: waist circumference \>102 cm in men and \>88 cm in women, triglycerides \>1.69 mmol/l or on treatment for elevated triglycerides, HDL \<1.04 mmol/l in men and \<1.3 mmol/l in women or on treatment for reduced HDL, blood pressure \>130/85 mmHg or on antihypertensive treatment, fasting glucose ≥5.6 mmol/l.

Statistical analysis {#s2c}
--------------------

Variables with skewed distribution including triglycerides, hsCRP, GGT, and fasting insulin were natural log transformed for statistical analyses. Continuous data are expressed as means ± SD. Categorical variables were compared by χ2 test. Anthropometric and metabolic differences between groups were tested after adjusting for gender using a general linear model with *post hoc* Bonferroni correction for multiple comparisons. To avoid overestimation of the model, we excluded those variables used as a part of the NAFLD fibrosis score calculation i.e. age, and BMI. A general linear model was used to determine the independent impact on eGFR values of several variables including smoking habit, glucose tolerance status, HOMA-IR index, diagnosis of metabolic syndrome, statin therapy, medications for diabetes, anti-hypertensive treatments, and gender.

A logistic regression analysis adjusted for gender, age, and BMI was used to determine the association between the study groups and CKD. A second logistic regression model adjusted for glucose tolerance status, statin therapy, and anti-hypertensive treatment in addition to gender was run to determine the association between the study groups and CKD. A *P* value \<0.05 was considered statistically significant. All analyses were performed using SPSS software program Version 16.0 for Windows.

Results {#s3}
=======

The clinical and biochemical features of the study group are reported in [Table 1](#pone-0088569-t001){ref-type="table"}. The mean age for the entire cohort was 54.1±13.5 yrs. Of the 570 subjects examined, 220 (38.6%) had NGT, 63 (11.1%) had IFG, 112 (19.6%) had IGT, and 175 (30.7%) had type 2 diabetes. Metabolic syndrome was diagnosed in 392 (68.8%) individuals, and 368 (64.6%) subjects had hypertension treated with anti-hypertensive medications. A low probability of advanced liver fibrosis (NAFLD fibrosis score \<−1.455) was found in 41.4% of subjects, an intermediate probability of advanced liver fibrosis (NAFLD fibrosis score −1.455--0.676) was found in 48.9% of subjects, and a high probability of advanced liver fibrosis (NAFLD fibrosis score \>0.676) was found in 9.6% of subjects. As expected by stratifying subjects according to the NAFLD fibrosis score, individuals classified as at high or intermediate probability of liver fibrosis were older (*P*\<0.0001), had higher BMI (*P*\<0.0001) and AST/ALT ratio (*P*\<0.0001), lower platelet counts (*P*\<0.0001) and albumin levels (*P*\<0.0001), and were more likely to have elevated fasting glucose (*P*\<0.0001) or IFG/IGT/type 2 diabetes (*P*\<0.0001) as compared with those at low probability of liver fibrosis. A lower proportion of individuals classified as at high probability of liver fibrosis were current smokers (*P* = 0.04). Subjects classified as at high or intermediate probability of liver fibrosis were more likely to have metabolic syndrome (*P*\<0.0001) as compared with those at low probability of liver fibrosis. A higher proportion of individuals classified as at high probability of liver fibrosis were treated with insulin (*P* = 0.01) ([Table 1](#pone-0088569-t001){ref-type="table"}). A higher proportion of individuals classified as at high or intermediate probability of liver fibrosis were treated with statins (*P*\<0.0001) ([Table 1](#pone-0088569-t001){ref-type="table"}). In addition, significant differences between the three groups were observed with respect to anti-hypertensive treatments: a higher proportion of individuals classified as at high or intermediate probability of fibrosis were treated with ACE inhibitors, angiotensin receptor blockers and diuretics (*P*\<0.0001) ([Table 1](#pone-0088569-t001){ref-type="table"}).

10.1371/journal.pone.0088569.t001

###### Anthropometric and biochemical characteristics of the study subjects stratified according to fibrosis risk score.

![](pone.0088569.t001){#pone-0088569-t001-1}

  Variables                                         Whole study subjects   Low probability of fibrosis (\< −1.455)   Intermediate probability of fibrosis (−1.455--0.676)     High probability of fibrosis (\>0.676)       *P*
  ------------------------------------------------ ---------------------- ----------------------------------------- ------------------------------------------------------ -------------------------------------------- ----------
  Gender (Male/Female)                                    319/251                          126/110                                         162/117                                            31/24                        0.56
  Age *(yrs)*                                            54.1±13.5                        47.0±12.4                       57.7±11.1[d](#nt105){ref-type="table-fn"}         66.5±12.9[d](#nt105){ref-type="table-fn"}    \<0.0001
  BMI *(kg/m^2^)*                                         32.3±6.5                        30.5±5.3                         33.0±6.1[b](#nt103){ref-type="table-fn"}          36.9±9.3[d](#nt105){ref-type="table-fn"}    \<0.0001
  Waist circumference (c*m*)                               107±14                          102±12                           109±13[d](#nt105){ref-type="table-fn"}            116±17[d](#nt105){ref-type="table-fn"}     \<0.0001
  Current smokers No (%)                                102 (17.9%)                      50 (21.2%)                                       48 (17.2%)                         4 (7.3%)[a](#nt102){ref-type="table-fn"}      0.04
  SBP *(mmHg)*                                             135±18                          133±17                                           136±18                            144±23[d](#nt105){ref-type="table-fn"}     \<0.0001
  DBP *(mmHg)*                                             82±11                            82±10                                           82±11                                             81±12                        0.82
  Fasting glucose (*mg/dl*)                                113±47                           99±35                           120±46[d](#nt105){ref-type="table-fn"}            143±67[d](#nt105){ref-type="table-fn"}     \<0.0001
  2-h post-load glucose (*mg/dl*)                          137±45                          123±39                           148±48[d](#nt105){ref-type="table-fn"}            158±50[d](#nt105){ref-type="table-fn"}     \<0.0001
  Fasting insulin *(μU/ml)*                                 15±9                            14±9                             16±9[a](#nt102){ref-type="table-fn"}             18±10[a](#nt102){ref-type="table-fn"}       0.008
  Total cholesterol (*mg/dl*)                              197±40                          204±37                           193±40[b](#nt103){ref-type="table-fn"}            181±39[d](#nt105){ref-type="table-fn"}     \<0.0001
  HDL (*mg/dl*)                                            47±13                            48±13                                           47±13                                             45±12                        0.67
  Triglycerides (*mg/dl*)                                  144±71                          137±67                                           150±73                                            144±73                       0.14
  Uric acid (*mg/dl*)                                     5.5±1.4                          5.3±1.3                                         5.6±1.4                           6.3±1.8[d](#nt105){ref-type="table-fn"}     \<0.0001
  IGF-1 (*ng/ml*)                                          144±57                          158±57                           137±54[d](#nt105){ref-type="table-fn"}            117±46[d](#nt105){ref-type="table-fn"}     \<0.0001
  eGFR (ml/min/1.73m^2^)                                   93±25                           102 ±27                          87±21[d](#nt105){ref-type="table-fn"}             82±24[d](#nt105){ref-type="table-fn"}      \<0.0001
  CKD No, (%)                                            38 (6.7%)                        6 (2.5%)                                        21 (7.5%)                                         11 (20.0%)                   \<0.0001
  hsCRP (*mg/l*)                                          4.3±3.9                          3.9±3.7                                         4.3±3.7                           5.9±5.1[c](#nt104){ref-type="table-fn"}      0.003
  Fibrinogen (*mg/dl*)                                     318±80                          307±81                           322±78[a](#nt102){ref-type="table-fn"}            343±85[b](#nt103){ref-type="table-fn"}      0.003
  ALT (*UI/l*)                                             30±18                            32±19                           29±16[a](#nt102){ref-type="table-fn"}             23±16[c](#nt104){ref-type="table-fn"}      \<0.0001
  AST (*UI/l*)                                             25±14                            23±11                                           25±12                             30±25[b](#nt103){ref-type="table-fn"}        0.01
  AST/ALT ratio                                          0.94±0.44                        0.83±0.27                       0.94±0.33[c](#nt104){ref-type="table-fn"}         1.41±0.96[d](#nt105){ref-type="table-fn"}    \<0.0001
  GGT (*UI/l*)                                             36±30                            35±26                                           35±28                                             46±44                        0.25
  Platelet count (*x10^9^/l*)                              249±71                          288±76                           230±49[d](#nt105){ref-type="table-fn"}            179±43[d](#nt105){ref-type="table-fn"}     \<0.0001
  Albumin (*g/dl*)                                       4.43±0.35                        4.52±0.38                       4.41±0.30[d](#nt105){ref-type="table-fn"}         4.14±0.29[d](#nt105){ref-type="table-fn"}    \<0.0001
  HOMA-IR index                                           4.2±3.7                          3.5±2.9                         4.5±2.9[b](#nt103){ref-type="table-fn"}           6.5±7.5[d](#nt105){ref-type="table-fn"}     \<0.0001
  NFG/IFG/IGT/T2DM (No)                                220/63/112/175                   158/18/29/31                     58/39/69/113[d](#nt105){ref-type="table-fn"}       4/6/14/31[d](#nt105){ref-type="table-fn"}    \<0.0001
  Metabolic syndrome No (%)                             392 (68.8%)                      127 (53.8%)                     219 (78.5%)[d](#nt105){ref-type="table-fn"}        46 (83.6%)[d](#nt105){ref-type="table-fn"}   \<0.0001
  Antidiabetic treatment (No)                                                                                                                                                                                           
  Diet/Oral hypoglycemic agents/Insulin                   66/59/50                         13/11/7                                         45/42/26                                           8/6/17                       0.01
  Therapy with statins No (%)                           144 (25.3%)                      38 (16.1%)                       82 (29.4%)[c](#nt104){ref-type="table-fn"}        24(43.6%)[d](#nt105){ref-type="table-fn"}    \<0.0001
  ACE inhibitor therapy, No (*%*)                       156 (27.4%)                      53 (22.5%)                       80 (28.7%)[b](#nt103){ref-type="table-fn"}        23(41.8%)[d](#nt105){ref-type="table-fn"}    \<0.0001
  Angiotensin receptor blocker therapy, No (*%*)        132 (23.2%)                       38(16.1%)                       77 (27.6%)[d](#nt105){ref-type="table-fn"}        17 (30.9%)[d](#nt105){ref-type="table-fn"}   \<0.0001
  Calcium channel blockers, No (*%*)                    117 (20.5%)                      46 (19.5%)                                       56 (20.1%)                                        15(27.3%)                      0.42
  Diuretics, No (*%*)                                   143 (25.1%)                      30 (12.7%)                       84 (30.1%)[d](#nt105){ref-type="table-fn"}        29 (52.7%)[d](#nt105){ref-type="table-fn"}   \<0.0001

Data are means ± SD. Insulin, triglyceride, hsCRP, and GGT levels were log transformed for statistical analysis, but values in the table represent a back transformation to the original scale. Categorical variables were compared by χ^2^ test. *P* values refer to results after analyses with adjustment for gender. M =  male; F =  female; BMI =  body mass index; SBP =  systolic blood pressure; DBP =  diastolic blood pressure; HDL =  high-density lipoprotein; hsCRP =  high sensitivity C-reactive protein; ALT =  alanine aminotransferase; AST =  aspartate aminotransferase; GGT =  gamma-glutamyltransferase; HOMA-IR =  homeostasis model assessment index of insulin resistance; IGF-1 =  insulin-like growth factor-1; eGFR =  estimated glomerular filtration rate; CKD =  chronic kidney disease; ACE =  angiotensin-converting-enzyme; NFG =  normal glucose tolerance; IFG =  impaired fasting glucose; IGT =  impaired glucose tolerance; T2DM =  type 2 diabetes.

*P*\<0.05 vs. Low risk of fibrosis group.

*P*\<0.01 vs. Low risk of fibrosis group.

*P*\<0.001 vs. Low risk of fibrosis group

*P*\<0.0001 vs. Low risk of fibrosis group.

As compared with individuals at low probability of liver fibrosis, both individuals at high probability of fibrosis and individuals at intermediate probability of fibrosis showed an unfavorable cardio-metabolic risk profile having significantly higher values of waist circumference, insulin resistance, as assessed by the HOMA-IR index, hsCRP, fibrinogen, serum uric acid as well as lower levels of IGF-1 ([Table 1](#pone-0088569-t001){ref-type="table"}). In addition individuals at high probability of fibrosis had higher systolic blood pressure values.

As compared with individuals at low probability of liver fibrosis, both individuals at high and those at intermediate probability of fibrosis exhibited lower value of eGFR (*P*\<0.0001) ([Table 1](#pone-0088569-t001){ref-type="table"}). These differences remained statistically significant after adjustment for smoking habit, glucose tolerance status, HOMA-IR index, diagnosis of metabolic syndrome, statin therapy, medications for diabetes, and anti-hypertensive treatments in addition to gender using a general linear model (*P* = 0.001) ([Table 2](#pone-0088569-t002){ref-type="table"}). Furthermore, the differences remained statistically significant after adjustment for individual components of the metabolic syndrome including waist circumference, blood pressure, HDL, triglycerides, and glucose values in addition to gender (*P*\<0.0001) ([Table 3](#pone-0088569-t003){ref-type="table"}).

10.1371/journal.pone.0088569.t002

###### General linear model with eGFR as the dependent variable.

![](pone.0088569.t002){#pone-0088569-t002-2}

  Variables                                F      *P*
  -------------------------------------- ------ --------
  Gender                                  1.62    0.20
  Current smokers No (%)                  0.19    0.66
  HOMA-IR index                           0.03    0.88
  Glucose tolerance status                0.13    0.72
  Metabolic syndrome diagnosis            0.57    0.45
  Antidiabetic treatment                  0.42    0.51
  Therapy with statins                    4.34    0.03
  ACE inhibitor therapy                   15.2   0.0001
  Angiotensin receptor blocker therapy    1.97    0.16
  Calcium channel blockers                0.02    0.96
  Diuretics                               10.6   0.001
  Fibrosis risk score                     6.99   0.001

eGFR =  estimated glomerular filtration rate; HOMA-IR =  homeostasis model assessment index of insulin resistance; ACE =  angiotensin-converting-enzyme.

10.1371/journal.pone.0088569.t003

###### General linear model with eGFR as the dependent variable.

![](pone.0088569.t003){#pone-0088569-t003-3}

  Variables                     F      *P*
  -------------------------- ------- --------
  Gender                      0.50     0.47
  Waist circumference         16.58   0.0001
  Fasting glucose             0.57     0.45
  HDL                         0.70     0.40
  Triglycerides               4.20     0.04
  Systolic blood pressure     15.57   0.0001
  Diastolic blood pressure    7.49    0.006
  Fibrosis risk score         17.96   0.0001

eGFR =  estimated glomerular filtration rate; HDL =  high-density lipoprotein.

When the analysis was restricted to the 175 subjects with IFG or IGT, both individuals at high and those at intermediate probability of fibrosis exhibited lower value of eGFR (95±19 and 100±26 ml/min/1.73 m^2^, respectively; *P* = 0.03) as compared with individuals at low probability of liver fibrosis (eGFR  = 110±25 ml/min/1.73 m^2^). Accordingly, when the analysis was restricted to the 175 subjects with type 2 diabetes, both individuals at high and those at intermediate probability of fibrosis exhibited lower value of eGFR (81±33 and 89±26 ml/min/1.73 m^2^, respectively; *P* = 0.001) as compared with individuals at low probability of liver fibrosis (eGFR  = 109±42 ml/min/1.73 m^2^).

Of the 570 subjects examined, 38 (6.7%) had CKD defined as eGFR \<60 ml/min/1.73 m^2^. A logistic regression model adjusted for gender, age, and BMI was used to compare the risk of individuals at high and at intermediate probability of fibrosis to have CKD as compared with individuals at low probability of fibrosis (the reference category). Individuals at high probability of fibrosis had a 5.1-fold increased risk of having CKD (OR 5.13, 95%CI 1.13--23.28; *P* = 0.03) and individuals at intermediate probability of fibrosis had a 3.0-fold increased risk of having CKD (OR 3.01, 95%CI 0.87--10.32; *P* = 0.07) as compared with individuals at low probability of fibrosis. After adjustment for glucose tolerance status, statin therapy, and anti-hypertensive treatment in addition to gender, individuals at high probability of fibrosis had a 3.9-fold increased risk of having CKD (OR 3.94, 95%CI 1.11--14.05; *P* = 0.03) as compared with individuals at low probability of fibrosis ([Table 4](#pone-0088569-t004){ref-type="table"}). Increased risk of CKD was also independently associated with glucose tolerance status (*P* = 0.03), and anti-hypertensive treatment (*P* = 0.002) ([Table 4](#pone-0088569-t004){ref-type="table"}).

10.1371/journal.pone.0088569.t004

###### Logistic regression analyses adjusted for gender of the association between study group subjects and CKD.
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                                                                                CKD      
  ----------------------------------------------------------------- ------ ------------- -------
  Individuals at low probability of fibrosis (reference category)     1         ---        ---
  Individuals at high probability of fibrosis                        3.94   1.11--14.05   0.03
  Glucose tolerance status                                           1.33   1.02--1.75    0.03
  Statin therapy                                                     1.09   0.51--2.32    0.80
  Anti-hypertensive treatment                                        1.04   1.01--1.06    0.002

CKD =  chronic kidney disease.

Discussion {#s4}
==========

It is increasingly recognized that both NAFLD and CKD are associated with a clustering of traditional and non-traditional cardio-metabolic risk factors, and predict the development of cardiovascular diseases [@pone.0088569-Go1]--[@pone.0088569-Sesti1], [@pone.0088569-Bugianesi1], [@pone.0088569-Ekstedt1]--[@pone.0088569-Targher3]. There is also evidence supporting the notion that adverse clinical outcomes are more frequent in patients with NASH rather than in individuals with simple liver steatosis [@pone.0088569-Ekstedt1]--[@pone.0088569-Marchesini1], [@pone.0088569-Targher1], [@pone.0088569-Targher5], [@pone.0088569-Yasui1], thus emphasizing the importance to assess more advanced form of NAFLD in individuals affected by liver steatosis. Several noninvasive scoring indexes combining clinical and laboratory variables have been developed in order to identify advanced fibrosis in individuals with NAFLD [@pone.0088569-Wai1]--[@pone.0088569-Demir1]. Employing one of these liver fibrosis scores, it has been shown that advanced fibrosis is associated with increased risk of cardiovascular mortality in individuals with NAFLD [@pone.0088569-Targher2], [@pone.0088569-Weiner2]. These findings coupled with the accessibility of a carefully characterized cohort of adult subjects have provided the rationale for investigating the relationship between advanced liver fibrosis, as determined by the NAFLD fibrosis score [@pone.0088569-Angulo2], in subjects with ultrasonography-diagnosed NAFLD and CKD. In this cross-sectional study, we report that individuals with high or intermediate probability of advanced liver fibrosis have lower eGFR as compared with individuals at low probability of liver fibrosis. These associations did not change after adjusting for several potential confounders including glucose tolerance status, diagnosis of metabolic syndrome or its individual components, treatments for dyslipidemia or hypertension. Accordingly, individuals with high probability of advanced liver fibrosis showed a 5.1-fold increased risk of having CKD as compared with individuals at low probability of fibrosis after adjustment for gender, age, and BMI. These data are consistent with those of two previous studies showing that CKD is associated with the severity of liver histopathology in adult individuals with biopsy-proven NAFLD [@pone.0088569-Targher5], [@pone.0088569-Yasui1].

The underlying mechanism(s) by which NAFLD/NASH may contribute to kidney dysfunction are still unsettled. The most obvious explanation is that classical and non-classical cardio-metabolic risk factors, such as abdominal obesity, impaired glucose homeostasis/diabetes, hypertension, dyslipidemia, insulin resistance, metabolic syndrome, elevated serum uric acid, plasma inflammatory and hemostatic factors, all of which are associated with NAFLD/NASH may be also important risk factors for the development of CKD. Accordingly, we found that individuals with high or intermediate probability of advanced liver fibrosis have an unfavorable cardio-vascular risk profile characterized by an increase in visceral adiposity, insulin resistance, inflammatory and pro-coagulant biomarkers such as hsCRP, and fibrinogen. However, the strong relationships between these cardio-metabolic risk factors, NAFLD/NASH, and renal dysfunction make it extremely difficult to determine the precise cause-effect relationship between the two disorders. A potential plausible candidate linking NAFLD/NASH and renal dysfunction merits a comment. A number of evidences suggest that IGF-1 has effects on glomerular hemodynamics by enhancing both renal plasma flow and GFR [@pone.0088569-Petta2], [@pone.0088569-Tsukahara1]--[@pone.0088569-Giordano1]. IGF-1 induces NO production in human umbilical vein endothelial cells, an effect that is abolished by a neutralizing IGF-1 receptor antibody [@pone.0088569-Tsukahara1], and renal vasodilation induced by IGF-1 is completely inhibited by an inhibitor of nitric oxide biosynthesis [@pone.0088569-Haylor1]. Studies in humans have shown that plasma IGF-1 levels are associated with GFR [@pone.0088569-Petta2], and intravenous infusion of rhIGF-1 increases renal plasma flow and GFR in healthy subjects [@pone.0088569-Giordano1]. We found that individuals with high or intermediate probability of advanced liver fibrosis have lower circulating IGF-1 levels as compared with individuals at low probability of liver fibrosis. These findings are consistent with previous studies showing that plasma IGF-1 concentration is a determinant of eGFR in hypertensive individuals [@pone.0088569-Petta2], and suggest that lower amounts of circulating IGF-1 associated with NAFLD/NASH [@pone.0088569-Arturi1], [@pone.0088569-Hribal1] could contribute to the reduced eGFR observed in individuals with high or intermediate probability of advanced liver fibrosis.

Several strengths and potential limitations of our study deserve comment. The major strengths of the study include the relatively large sample size with detailed anthropometric, clinical, and cardio-metabolic variables, the inclusion of both sexes, the ultrasound diagnosis of NAFLD performed by an experienced examiner who was blinded to the subjects\' clinical and biochemical data, the use of the CKD-EPI equation to estimate GFR, which is more accurate than the Modification of Diet in Renal Disease (MDRD) study equation to estimate renal function in obese subjects characterized by a higher GFR, the use of restrictive *post hoc* Bonferroni test to correct for multiple comparisons, and the exclusion of confounding conditions characterized by elevation in liver biomarkers such as heavy drinking, positivity for antibodies to HCV or HBsAg and cirrhosis (thus excluding patients with hepatorenal syndrome).

Nevertheless, the present study has certain limitations that require consideration. First, only serum creatinine levels and estimated GFR were available, introducing inaccuracy into estimates of GFR and, potentially, a misclassification of subjects with impaired kidney function. Although gold standard methods to measure GFR (isotope clearance measurements) may provide a more sensitive estimate of renal function, they are time-consuming and expensive procedures which are not feasible in large-scale studies. However, estimated GFR based on serum creatinine facilitates the detection, evaluation, and management of CKD, and many organizations such as the National Kidney Foundation recommend the use of prediction equations for the evaluation of kidney function in epidemiologic studies and in clinical practice. Thus, our findings may be applicable to public health practice settings. Second, the diagnosis of NAFLD was based on ultrasonography rather than on invasive methods such as percutaneous liver biopsy. Although ultrasonography is the common method of diagnosing for hepatic steatosis in clinical practice, its sensitivity is suboptimal when hepatic fat infiltration of the liver is \<30%. However, participants to our study had normal or only mildly elevated serum liver enzymes and, therefore, liver biopsy may be impractical for most of them. Additionally, all laboratory variables, including plasma glucose during OGTT were measured once, and small changes in the variables would therefore be expected if the same measurements were repeated on a different day. Although such an approach is common in clinical practice and in large epidemiologic studies, these assays are subject to intra-individual variability, and, therefore, some inaccuracy in the classification of subjects into glucose tolerance categories might have occurred. Furthermore, the information on alcohol intake was assessed by self-reported questionnaire, thus the real daily alcohol consumption may have been undervalued. Besides, our cohort includes outpatients recruited at a referral university hospital, representing subjects at increased risk for cardio-vascular disease, and, therefore, the present results may not be extendible to the general population. Moreover, all participants to the present study were White, and whether these findings also can be extended to other ethnic groups remains to be established. Finally, because of the cross-sectional design of this study, the present findings reflect only an association with prevalent and not incident kidney dysfunction, and therefore no definitive cause and effect relationship can be inferred.

The present cross-sectional findings may have both clinical and public health implications. Impaired renal function and NAFLD/NASH are two worldwide health problems due their devastating adverse outcomes, including end-stage renal disease, cirrhosis, hepatocellular carcinoma, and increased cardiovascular morbidity and mortality. Therefore, it appears necessary to identify those individuals who are at greatest risk for hepatic and renal diseases. The use of noninvasive scoring indexes for the prediction of fibrosis in subjects with NAFLD may be useful to identify those patients who need more stringent clinical surveillance aimed at preventing development or progression of both liver and renal complications.
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